Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Asima Hussaini

Internal Medicine Bourbonnais, IL Medical Doctor

NPI 1437110970 CMS profile 291337

400 Riverside Dr Ste 2800, Bourbonnais, IL 60914

Open in the dashboard

General payments

$6,153

351 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Asima Hussaini of Bourbonnais, IL is reported in the CMS Open Payments database as having received $6,153 across 351 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $912 41
2024 General $839 44
2023 General $880 56
2022 General $1,017 58
2021 General $874 50
2020 General $616 43
2019 General $1,015 59

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Asima Hussaini
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Asima Hussaini were reported at $912. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Asima Hussaini Internal Medicine median Middle half National median
2019 $1,015 $159 $48–$570 $163
2020 $616 $119 $33–$402 $114
2021 $874 $135 $37–$521 $132
2022 $1,017 $141 $42–$496 $149
2023 $880 $149 $45–$519 $160
2024 $839 $154 $47–$537 $164
2025 $912 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $704 40 payments
  2. Novo Nordisk Inc $696 45 payments
  3. AbbVie, Inc. $664 45 payments
  4. Lilly USA, LLC $454 26 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $444 23 payments
  6. AstraZeneca Pharmaceuticals LP $416 20 payments
  7. Amgen Inc. $415 31 payments
  8. Organogenesis Inc. $409 14 payments
  9. Pfizer Inc. $302 18 payments
  10. Janssen Pharmaceuticals, Inc $278 11 payments
  11. Other $1,372 78 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,153 351 payments
Products named General payments · program years 2019–2025
  1. Ozempic $540 36 payments
  2. TRELEGY ELLIPTA $422 25 payments
  3. SHINGRIX $309 17 payments
  4. Repatha $291 21 payments
  5. AIMOVIG $282 20 payments
  6. XARELTO $278 11 payments
  7. UBRELVY $252 23 payments
  8. Apligraf $239 7 payments
  9. JARDIANCE $234 13 payments
  10. FARXIGA $220 10 payments
  11. Other $5,336 317 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 85 drugs

Part D claims

4,536

Median for Internal Medicine: 777

Drug cost

$438,670

Median for Internal Medicine: $73,373

Branded share of claims

17.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 64 $73,177
Jardiance Empagliflozin Brand 39 $59,730
Ozempic Semaglutide Brand 35 $55,039
Farxiga Dapagliflozin Propanediol Brand 39 $52,142
Eliquis Apixaban Brand 26 $35,124
Januvia Sitagliptin Phosphate Brand 29 $26,114
Tresiba Flextouch U-200 Insulin Degludec Brand 18 $21,155
Xarelto Rivaroxaban Brand 12 $19,155
Tradjenta Linagliptin Brand 12 $16,106
Breo Ellipta Fluticasone/Vilanterol Brand 28 $14,024

The 10 drugs with the highest cost, of 85 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 52 billing codes

Paid by Medicare

$149,217

Of which drugs: $31,680

Medicare patients

358

Average age 75

Services billed

1,870

227 women, 131 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Chronic kidney disease 38%
Diabetes 31%
Ischemic heart disease 31%
Heart failure 26%
Atrial fibrillation 24%
Osteoporosis 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 87 87 $25,282
Vaccine for influenza for injection into muscle 90662 Office 67 69 $5,586

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $74
  • Lilly USA, LLC $65
$139 39 —
Ozempic
  • Novo Nordisk Inc $65
$65 35 —
VRAYLAR
  • AbbVie, Inc. $59
$59 — —
TRINTELLIX
  • Takeda Pharmaceuticals U.S.A., Inc. $37
$37 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $35
$35 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

351 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record